JARDIANCE ® PROTECTION *
JARDIANCE ® PROTECTION *
EXPANDED † 1
†
Start JARDIANCE ® with metformin. No HbA1c requirement. 1
†
Simplified PBS access with no HbA1c requirement: 1
• CV Disease, or
• High risk of a CV event ‡, or
• First Nations Australians
‡
Defined as ≥10 % estimated risk in the next 5 years: www. cvdcheck. org. au.
THE ONLY
oral anti-diabetic medication indicated to reduce the risk of CV death * 2, 3
* In adult patients with T2D and established CV Disease( CAD, PAD, MI or stroke) on top of SOC. 2
PBS Information: JARDIANCE ®: Authority Required( STREAMLINED). Type 2 Diabetes. Refer to PBS Schedule for full Authority Required Information.
BEFORE PRESCRIBING, PLEASE REVIEW THE FULL PRODUCT INFORMATION AVAILABLE FROM BOEHRINGER INGELHEIM AT WWW. BOEHRINGER-INGELHEIM. COM. AU / PI OR BY SCANNING THE QR CODE.
Use of this medicinal product in paediatric patients aged 10 to 17 years with type 2 diabetes mellitus is subject to additional monitoring in Australia. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse events at www. tga. gov. au / reporting-problems
References: 1. Pharmaceutical Benefits Scheme. Available at: www. pbs. gov. au. Accessed June 2025. 2. JARDIANCE ® Product Information. 3. Therapeutic Goods Administration. Available at: www. tga. gov. au. Accessed June 2025.
Abbreviations: CAD, coronary artery disease; CV, cardiovascular; MI, myocardial infarction; PAD, peripheral artery disease; SOC, standard of care; T2D, type 2 diabetes.
Boehringer Ingelheim Pty Limited, ABN 52 000 452 308. 78 Waterloo Road, North Ryde, NSW 2113 Australia. Copyright © 2025. PC-AU-104495. Prepared July 2025. BOEH0631.